4-ho-mipt/dipt

Got mine, but they are lowest on my list. I've done nothing but tryptamines. They are so familiar to me that it is a bit like drinking my own bath water now. I need to take a break from them and explore some of the other arrangements along PEA instead, for I have a terrible sample rate of this one. 2c-e first, then 2c-t-7, then maybe 2c-p.

 

Here's what a friend of mine had to say about a 15mg dose of 4-ho-mipt he tried:

This isn't me doing some "SWIM" type crap.. a friend actually did dose. :toetap05:

 

I'm glad that these are more potent than 4-aco-dmt...that stuff seems to vanish too fast

 

im not too sure if the fumurate iprocin is more potent than the fumurate 4acodmt mg for mg. I dosed ~22 mg 4hodipt fumurate in a capsule (i assume from effects felt because the salt is not listed on web site) saturday night. The first effects were felt within 15 minutes, although not fully developed until 1 hour after ingestion. The standard tryptamine visuals were there, Such as wavy lines, changing colors, and objects appearing to sway. The only downside was some tremors in my legs. Although i was cold and i am sure that influenced it some but not completely. There was not much of a body load overall but some was felt on the come up. Once near the end of the peak we went outside and smoked a blunt while watching the snow. The snow glistened in the air while the street lights reflected off of it, for a very nice effect. It was cold outside so we didnt stick around after the blunt. We finished watching our 2nd movie at about 4 hours in. At that point me and my buddy decided we were basically baseline so went back to my house popped 1 mg xanax and was out easily. Overall an enjoyable experience but i will shoot for 30 mg next go. I had a problem with the correct dose and found a salt dose calculator over at bluelight i could post if anyone is interested

 

You are supposed to learn to enjoy psychedelic tremors... Or learn how to control them in a good way.

 

they are erotica

 

they are one of the best parts of dancing!

 

the only tremors i have learned to enjoy quite alot, are the 2c-e tremors i get. oooooooo maaaaaannnnn. those are goood. lol. other tremors ive gotten have not been as erotic those.

 

http://www.cognitiveliberty.org/dll/2CT7_ sched_intent.htm

2-C-T-7: Intent to Schedule

July 18, 2002

For a CCLE alert about this, click here.

Addendum Sept. 2002: 2C-T-7 Scheduled.



2-C-T-7: Intent to Schedule

[Federal Register: July 18, 2002 (Volume 67, Number 138)]
[Proposed Rules]
[Page 47343-47345]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18jy02-24]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[DEA-227N]


Schedules of Controlled Substances: Temporary Placement of 2,5-
Dimethoxy-4-(n)-propylthiophenethylamine Into Schedule I

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Notice of intent.

-----------------------------------------------------------------------

SUMMARY: The Deputy Administrator of the Drug Enforcement
Administration (DEA) is issuing this notice of intent to temporarily
place 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) into
Schedule I of the Controlled Substances Act (CSA) pursuant to the
temporary scheduling provisions of the CSA. This intended action is
based on a finding by the DEA Deputy Administrator that the placement
of 2C-T-7 into Schedule I of the CSA is necessary to avoid an imminent
hazard to the public safety. Finalization of this action will impose
the criminal sanctions and regulatory controls of a Schedule I
substance on the manufacture, distribution, and possession of 2C-T-7.

FOR FURTHER INFORMATION CONTACT: Frank Sapienza, Chief, Drug and
Chemical Evaluation Section, Office of Diversion Control, Drug
Enforcement Administration, Washington, DC 20537, Telephone (202) 307-
7183.

SUPPLEMENTARY INFORMATION:

What Is Temporary Scheduling?

The Comprehensive Crime Control Act of 1984 (Pub. L. 98-473), which
was signed into law on October 12, 1984, amended section 201 of the
Controlled Substances Act (CSA) (21 U.S.C. 811) to give the Attorney
General the authority to temporarily place a substance into Schedule I
of the CSA for one year without regard to the requirements of 21 U.S.C.
811(b) if he finds that such action is necessary to avoid an imminent
hazard to the public safety. The Attorney General may extend the
temporary scheduling up to 6 months. A substance may be temporarily
scheduled under the emergency provisions of the CSA if that substance
is not listed in any other schedule under section 202 of the CSA (21
U.S.C. 812) or if there is no exemption or approval in effect under 21
U.S.C. 355 for the substance. The Attorney General has delegated his
authority under 21 U.S.C. 811 to the Deputy Administrator of DEA (28
CFR 0.100).

What Criteria Must Be Considered in Determining Temporary Scheduling?

In making a finding that placing a substance temporarily into
Schedule I of the CSA is necessary to avoid an imminent hazard to the
public safety, the Deputy Administrator is required to consider three
of the eight factors set forth in section 201(c) of the CSA (21 U.S.C.
811(c)). These factors are as follows: (4) History and current pattern
of abuse; (5) The scope, duration and significance of abuse; and (6)
What, if any, risk there is to the public health.

What Is 2,5-Dimethoxy-4-(n)-propylthiophenethylamine?

2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), a
phenethylamine, is structurally related to the Schedule I
phenethylamine 4-bromo-2,5-dimethoxyphenethylamine (2C-B), and other
hallucinogens (e.g., 2,5-dimethoxy-4-methylamphetamine (DOM), and 1-(4-
bromo-2,5-dimethoxyphenyl-2-aminopropane (DOB)) in Schedule I of the
CSA. 2C-T-7 has those structural features of phenethylamines which are
necessary for stimulant and/or hallucinogenic activity; 2C-T-7 is a
sulfur analogue of 2CB. Based on these structural features. 2C-T-7 is
likely to have a pharmacological profile similar to 2CB and other
Schedule I hallucinogens. The similarity in the effects of 2C-T-7 and
2CB has been supported by Shulgin and Shulgin (Pikal: A Chemical Love
Story; pp. 569-570, 1991) and by ``self-reports'' on the Internet.
Shulgin and Shulgin (1991) reported that at an oral dose of 20 mg or 30
mg, 2C-T-7 produced visual hallucinations. They concluded that in terms
of being an acceptable hallucinogen, 2C-T-7 was comparable to 2CB and
mescaline. Self-reports on the Internet have described the
hallucinations resulting from the self-administration of 2C-T-7 as
being very 2CB-like; consisting of persistent multiple images, overlaid
patterns, and trails. The subjective effects of 2C-T-7 have also been
described as being similar to those of 2CB; mood lifting, sense of well
being, emotionally, volatility, increased appreciation of music, and
psychedelic ideation.
DEA is not aware of any approved therapeutic use of 2C-T-7 in the
United States. The safety of this substance for use in humans has never
been demonstrated.

What Information Was Considered in Respect to Making the Finding of
Imminent Hazard to the Public Health?

DEA, as required by 21 U.S.C. 811(h)(3), considered the following
three factors set forth in paragraphs (4), (5) and (6) of 21 U.S.C.
811(c) in its decision to temporarily schedule 2C-T-7. The information
relevant to the three factors is summarized below.

21 U.S.C. 811(c)(4) Its History and Current Pattern of Abuse

The abuse of stimulant/hallucinogenic substances in popular all
night dance parties (raves) and in other venues has been a major
problem in Europe since the 1990s. In the past several years, this
activity has spread to the United States. The Schedule I controlled
substance MDMA and its analogues, collectively known as Ecstasy, are
the most popular drugs abused at these raves. Their abuse has been
associated with both acute and long-term public health and safety
problems. These raves have also become venues for the trafficking and
abuse of ``new non-controlled'' substances in place of or in addition
to ``Ecstasy.'' 2C-T-7 is one such substance.
Illicit use of 2C-T-7 was first reported in Germany in 1997. 2C-T-7
was placed under the control of German law on January 20, 1998. In
October of 1999, 2C-T-7 tablets were being sold in the Netherlands
under the trade name ``Blue Mystic''. Illicit use of 2C-T-7 was
reported in Sweden in January of 2000. Currently 2C-T-7 is controlled
under the Swedish law pertaining to goods which are dangerous to the
public. French Customs authorities reported seizing tablets in 2001
that contained 10 mg of 2C-T-7.
Abuse of 2C-T-7 in the United States was first reported in 1997; an
individual posted his experience associated with the oral ingestion of
20 mg of 2C-T-7 on the Lycaeum website on the Internet. In the year
2000, the abuse of 2C-T-7 by young adults began to spread in the United
States as evidenced by widespread discussion on drug website forums and
the sale of the substance from an Internet company. The information
being discussed on these websites includes the route of administration,
recommended doses, and narratives from individuals describing their
experiences and effects after self-administering 2C-T-7.
Self-reported experiences and other information posted on these
websites indicate that 2C-T-7 is being abused orally (10-50 mg) or
intranasally; the

[[Page 47344]]

oral route is the most common route of abuse. The powder is being mixed
in liquids or placed in gelatin capsules. Information posted on these
websites indicates that 2C-T-7 is being taken alone or with other
drugs; such as MDMA, ketamine, cannabis, N,N-disopropyl-5-
methoxytryptamine (``Foxy Methoxy'') and N,N-dipropyltryptamine (DPT).
Information gathered by DEA indicates that 2C-T-7 has been
purchased in powder form over the Internet and distributed as such. In
the United States, capsules containing 2C-T-7 powder also have been
encountered; whereas in the Netherlands (``Blue Mystics''), and in
Canada (``Red Raspberry'') the bulk powder is being processed into
tablets.

21 U.S.C. 811(c)(5) the Scope, Duration and Significance of Abuse

State and local law enforcement agencies reported 2C-T-7 exhibits
seized in the states of Texas and Wisconsin. In Wisconsin, two
unrelated exhibits were submitted to the Wisconsin State Crime
Laboratory for analysis; the first exhibit consisted of two clear
capsules containing 16 to 18 milligrams of white powder and two paper
packets. One packet contained 450 milligrams of tan powder and the
other paper packet contained 869 milligrams. The powder in these
exhibits was identified as 2C-T-7. These two capsules were sold to an
informant as ``Tweety-Bird Mescaline.'' The second exhibit analyzed by
the Wisconsin State Crime Laboratory was shown to be a mixture of 2C-T-
7 and N,N-dipropyltryptamine (DPT). 2C-T-7 has also appeared in illicit
traffic in Tennessee, Washington, and Oklahoma, as evidenced by the 2C-
T-7 related deaths in these states. It is being sold under the ``street
names'' Blue Mystic, T7, Beautiful, Tweety-Bird Mescaline or Tripstay.
To date, DEA has not identified a clandestine laboratory synthesizing
2C-T-7.

21 U.S.C. 811(c)(6) What, If Any, Risk There Is to Public Health

2C-T-7 shares those structural similarities with 2CB and other
phenethylamines (i.e., DOB, and DOM), which makes it likely to produce
similar public health risks. Sensory distortion and impaired judgment
can lead to serious consequences for both the user and the general
public. 2C-T-7 can have lethal effects when abused alone or in
combination with other illicit drugs. To date, three deaths have been
associated with the abuse of 2C-T-7. The first death occurred in
Oklahoma during April of 2000; a young healthy male overdosed on 2C-T-7
following intranasal administration. The co-abuse of 2C-T-7 with MDMA
will pose a significant health risk if 2C-T-7 popularity increases in
the same venues as with MDMA. The co-abuse of 2C-T-7 with MDMA has
resulted in lethal effects. The other two 2C-T-7 related deaths
resulted from the co-abuse of 2C-T-7 with MDMA. They both occurred in
April of 2001. One young man died in Tennessee while another man died
in the state of Washington.

What Other Factors Were Taken Into Consideration?

Additionally, DEA has considered the three criteria for placing a
substance into Schedule I of the CSA (21 U.S.C. 812). The data
available and reviewed for 2C-T-7 indicate that it has a high potential
for abuse, no currently accepted medical use in treatment in the United
States and is not safe for use under medical supervision.

What Is The Role of the Assistant Secretary for Health in Temporary
Scheduling?

As required by section 201(h)(4) of the CSA (21 U.S.C. 811(h)(4)),
the Deputy Administrator has notified the Assistant Secretary for
Health, delegate of the Secretary of Health and Human Services, of his
intention to temporarily place 2C-T-7 into Schedule I of the CSA.
Comments submitted by the Assistant Secretary for Health in response to
this notification, including whether there is an exemption or approval
in effect for 2C-T-7 under the Federal Food, Drug and Cosmetic Act,
shall be taken into consideration before a final order is published.
Based on the above data, the continued distribution and abuse of
2C-T-7 poses an imminent risk to the public safety. There are no
recognized therapeutic uses of this substance in the United States.
In accordance with the provisions of section 201(h) of the CSA (21
U.S.C. 811(h)) and 28 CFR 0.100, the Deputy Administrator has
considered the available data and the three factors required for a
determination to temporarily schedule 2C-T-7 under the CSA and finds
that placement of 2C-T-7 into Schedule I of the CSA is necessary to
avoid an imminent hazard to the public safety.
Because the Deputy Administrator finds that it is necessary to
temporarily place 2C-T-7 into Schedule I to avoid an imminent hazard to
the public safety, the final order, if issued, will be effective on the
date of publication in the Federal Register. 2C-T-7 will be subject to
the regulatory controls and administrative, civil and criminal
sanctions applicable to the manufacture, distribution, possession,
importing and exporting of a Schedule I controlled substance under the
CSA. Further, it is the intention of the Deputy Administrator to issue
such a final order as soon as possible after the expiration of thirty
days from the date of publication of this notice and the date that
notification was transmitted to the Assistant Secretary for Health.

Regulatory Certifications

Regulatory Flexibility Act

The Deputy Administrator hereby certifies that this rulemaking has
been drafted in accordance with the Regulatory Flexibility Act (5
U.S.C. 605(b)), has reviewed this regulation, and by approving it
certifies that this regulation will not have a significant economic
impact on a substantial number of small entities. This action provides
a notice of intent to temporarily place 2C-T-7 into Schedule I of the
Controlled Substances Act.

Executive Order 12988

This regulation meets the applicable standards set forth in
Sections 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice
Reform.

Executive Order 13132 Federalism

This rule will not have substantial direct effects on the States,
on the relationship between the national government and the States, or
on the distribution of power and responsibilities among the various
levels of government. Therefore, in accordance with Executive Order
13132, it is determined that this rule will not have sufficient
federalism implications to warrant the preparation of a Federalism
Assessment.

Unfunded Mandates Reform Act

This rule will not result in the expenditure by State, local and
tribal governments, in the aggregate, or by the private sector, of
$100,000,000 or more in any one year, and it will not significantly or
uniquely affect small governments. Therefore, no actions were deemed
necessary under provisions of the Unfunded Mandates Reform Act of 1995.

Small Business Regulatory Enforcement Fairness Act of 1996

This rule is not a major rule as defined by Sec. 804 of the Small
Business Regulatory Enforcement Fairness Act of 1996. This rule will
not result in an annual effect on the economy of $100,000,000 or more;
a major increase in costs or prices; or significant adverse

[[Page 47345]]

effects on competition, employment, investment, productivity,
innovation, or on the ability of United States-based companies to
compete with foreign-based companies in domestic and export markets.

List of Subjects in 21 CFR part 1308

Administrative practice and procedure, Drug traffic control,
Narcotics, Prescription drugs, Reporting and Recordkeeping
requirements.
Under the authority vested in the Attorney General by Section
201(h) of the CSA (21 U.S.C. 811(h)), and delegated to the Deputy
Administrator of the DEA by Department of Justice regulations (28 CFR
0.100), the Department Administrator hereby intends to order that 21
CFR Part 1308 be amended as follows:

PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES

1. The authority citation for 21 CFR Part 1308 continues to read as
follows:

Authority: 21 U.S.C. 811, 812, 871b, unless otherwise noted.

2. Section 1308.11 is to be amended by adding paragraph (g)(5) to
read as follows:


Sec. 1308.11 Schedule I.

* * * * *
(g) * * *
(5) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its
optical isomers, salts and salts of isomers--7348.
* * * * *

Dated: July 9, 2002.
John B. Brown, III,
Deputy Administrator.
[FR Doc. 02-17902 Filed 7-17-02; 8:45 am]
BILLING CODE 4410-09-M